Spurious Drugs Issue: Indian Government Proposes Cash Rewards For Informers; Industry Supportive
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Grappling with increasing incidents of spurious drugs, the Indian health ministry has proposed an incentive scheme for "whistle blowers" who provide credible information and help the government in confiscating fake drugs, cosmetics or medical devices
You may also be interested in...
India’s Second Stab At Whistle Blower Policy To Curb Spurious Drug Trade
India is making renewed efforts to encourage whistle blowers to share leads and help weed out spurious drugs from the Indian market while blocking exports of such consignments.
Sanofi-Aventis India In Damage Control Mode As Local Press Errs And Says Combiflam Banned, Instead Of Comiflam
MUMBAI - The Indian arm of French multinational Sanofi Aventis went into a speedy damage control mode after several vernacular newspapers incorrectly reported that one of its biggest revenue earners Combiflam (ibuprofen/paracetamol) was banned following an order of the State Drug Authorities in Rajasthan - a state in Western India - under the provisions of the Drugs & Cosmetics Act
Sanofi-Aventis India In Damage Control Mode As Local Press Errs And Says Combiflam Banned, Instead Of Comiflam
MUMBAI - The Indian arm of French multinational Sanofi Aventis went into a speedy damage control mode after several vernacular newspapers incorrectly reported that one of its biggest revenue earners Combiflam (ibuprofen/paracetamol) was banned following an order of the State Drug Authorities in Rajasthan - a state in Western India - under the provisions of the Drugs & Cosmetics Act